This new series profiles the members of edie's 30 Under 30 - a nomination-based community of 30 hugely talented young ...

Genpact's President and CEO, Balkrishan "BK" Kalra, expressed confidence in the company's trajectory, highlighting strong quarterly growth, particularly in the Data-Tech-AI segment, and a record $5.7 ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

The widely followed cryptocurrency analyst Benjamin Cowen is warning that Ethereum (ETH) could slide further against Bitcoin ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Kura Oncology (KURA – Research Report) today. The company’s shares closed yesterday at ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

President Donald Trump has continued his shake-up of NLRB leadership by firing Acting General Counsel (GC) Jessica Rutter and replacing her ...

TD Cowen adjusted its outlook on Alphabet stock (NASDAQ:GOOGL), decreasing the price target to $220 from the previous $225. The firm, however, continues to recommend a Buy rating for the tech giant's ...

Noting that Ambry is a profitable testing laboratory that generates more than $300 million of revenue annually, the investment bank thinks that the deal will enable TEM to start generating positive ...

In a report released today, Marc Bianchi from TD Cowen maintained a Buy rating on NOV (NOV – Research Report), with a price target of $22.00.